Dual Targeting Relapsed Myeloma Trial Achieves Major PFS Gains

The Dual Targeting Relapsed Myeloma Trial centers on a dual-targeting regimen of teclistamab-cqyv and talquetamab-tgvs that produced an 89 percent reduction in the risk of disease progression or death along with a 62 percent reduction in mortality risk among patients with relapsed or refractory multiple myeloma who had received one to four prior therapies. This result emerged from the first Phase 3 evaluation of a bispecific antibody combination directed simultaneously at B-cell maturation antigen and G protein-coupled receptor class C group 5 member D. The data position the regimen as the strongest progression-free survival signal observed to date among bispecific approaches in this setting.

89 Percent Risk Cut in Dual Targeting Relapsed Myeloma Trial

The MonumenTAL-6 study employed a three-arm randomized design that compared the dual bispecific regimen and a talquetamab-tgvs plus pomalidomide arm against investigator choice of either elotuzumab-pomalidomide-dexamethasone or pomalidomide-bortezomib-dexamethasone. An independent data monitoring committee reviewed the first interim analysis and recommended unblinding on the basis of statistically significant progression-free survival gains. The primary endpoint of progression-free survival assessed by independent review committee was supplemented by overall survival as a key secondary endpoint, allowing direct linkage between hazard ratios and mortality outcomes.

Hazard Ratios Signal Additive Effect

The dual-target arm recorded a hazard ratio of 0.11 for progression or death and 0.38 for death, values that exceed the corresponding 0.27 hazard ratio for progression or death observed in the talquetamab-tgvs plus pomalidomide arm. Both investigational regimens demonstrated overall safety profiles aligned with the established toxicities of each component agent, including cytokine release syndrome and neurologic events managed through step-up dosing. These quantitative separations from standard-of-care comparators indicate that simultaneous engagement of two distinct myeloma surface antigens yields additive clinical effect beyond single-target or immunomodulatory combinations.

Ad

Off-the-Shelf Access Shapes Payer Models

Health technology assessment bodies evaluating earlier-line use will confront the need to translate the observed hazard ratios into incremental cost-effectiveness ratios that account for reduced progression events and extended survival. The off-the-shelf administration format of the bispecific regimen may influence budget-impact models by avoiding the infrastructure requirements associated with cellular therapies while still delivering deep responses in patients previously exposed to anti-CD38 and lenalidomide agents. Payers will therefore require explicit modeling of subsequent-line therapy displacement and monitoring costs tied to cytokine release syndrome and infection prophylaxis when determining coverage criteria for this dual-target approach.